vimarsana.com

Card image cap

ArriVent BioPharma will apply the IPO cash toward furmonertinib, which the biotech says could offer advantages over Takeda Pharmaceutical and Johnson & Johnson drugs that address the same lung cancer target. It’s the second biotech IPO of this week, following CG Oncology.

Related Keywords

China , Japan , Japanese , Arrivent Biopharma , Johnson Rybrevant , Allist Pharma , Newtown Square , Nasdaq , Federal Reserve , Pennsylvania Based Arrivent , Shanghai Based Allist , Alto Neuroscience , Metagenomi Technologies , Weight Loss , Obesity , Verweight , Diabetes , Massachusetts , Medical Devices , Startups , Healthcare Innovation , Medcity News , San Francisco , Life Sciences , Accelerator , Rock Health , Startup Advice , Startup Funding , Patient Monitoring System , Otion Sensors , Dc , Healthcare It , Washington , Foodborne Pathogens , Iagnostics Company , Iagnostic Platforms , Minimally Invasive Surgery , Aser Surgery , Cambridge , Dealflow , Hospitals , Wellpoint , Ealthways , Ealth And Wellness , Mployee Wellness Programs , Investing , Wellness , Medtronic , Hanghai Innovation Center , R D , Mdt , Minneapolis , Minnesota , Publics , Twin Cities , Ulcerative Colitis , Abbott Labs , Humira , Doctors , Pharmaceuticals , Skin Disorders , D Anderson Cancer Center , Cancer , Texas , Renal Denervation , St Jude Medical , Stj , Emr , Hr , Electronic Health Records , Electronic Medical Records , Certified Emr , Ehr , Advanced Cellular Technology , Amyotrophic Lateral Sclerosis , Embryonic Stem Cells , Geron Corporation , Lou Gehrigs Disease , Macular Degeneration , Regenerative Medicine , Spinal Cord Damage , Value Based Healthcare System , Obamacare , Ee For Service Model , California , Cleveland , Health Insurance , Insurance , Ohio , Pennsylvania , Politics , Cancer Treatment Options Library , Aetna , Pet , Aet , Health It , Phi , Philadelphia , Biopharma Nl , Biotech Ipo , Dancer , Clinical Trials , Non Small Cell Lung Cancer , ,

© 2024 Vimarsana

vimarsana.com © 2020. All Rights Reserved.